HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ultima distribution

This article was originally published in The Rose Sheet

Executive Summary

Revlon will continue to support its Ultima brand domestically and abroad despite discontinuation of the brand in J.C. Penney, Elizabeth Kenny, senior VP-marketing for Almay and the Portfolio Brands says. Discontinuation will not have a "significant" impact on Revlon's overall business, as business in Penney's represents less than 1% of consolidated sales, exec adds. Statement follows J.C. Penney's announcement that it is downsizing its cosmetics department (1"The Rose Sheet" Feb. 3, 2003, p. 3)...

You may also be interested in...



Avon Retail Strategy BeComing Direct-Sell As Penney’s Minimizes Cosmetics

Avon plans to reposition the beComing beauty brand in the U.S. by folding the retail collection into its direct-sell business and ending its partnership with J.C. Penney, which announced it is de-emphasizing cosmetics sales

DevaCurl Faces Multiple Class Actions As Latest Brand Linked To Hair Loss

The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.

Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.

UsernamePublicRestriction

Register

RS010962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel